An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin (A06-295)
|First Submitted Date ICMJE||October 10, 2008|
|First Posted Date ICMJE||October 13, 2008|
|Last Update Posted Date||May 19, 2015|
|Start Date ICMJE||November 2008|
|Primary Completion Date||December 2012 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Plasma levels of rifampin and lopinavir-ritonavir (pharmacokinetics). [ Time Frame: 15, 45 and 180 days post-study treatment start ]|
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||Complete list of historical versions of study NCT00771498 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin|
|Official Title ICMJE||An Evaluation of the Pharmacological Interaction of Lopinavir 800mg - Ritonavir 200mg Combination and Rifampin in Subjects Presenting Tuberculosis, With Contraindication for Antiretroviral Regimens Including Efavirenz|
This is a pharmacokinetic, descriptive, open-label, prospective, multicentric, national study in Aids and tuberculosis co-infected patients, to be laboratory and clinically monitored during the treatment with lopinavir-ritonavir and rifampin medications.
Study population: Thirty patients older than 18 years, both male and female, which present active tuberculosis and failure or contraindication for any motive to an efavirenz will be selected to participate in the study.
Some attempts have been made to evaluate the pharmacokinetics of lopinavir using ritonavir as booster by some researchers with dosages of 400/100 and 533/133 mg (the last dosage would be achieved with an additional capsule of lopinavir/ritonavir) but the results were disappointing because AUC was importantly decreased with the introduction of rifampin in both situations (BERTZ et al, 2000).
La Porte et al (2004) presented the results of a pharmacokinetic study using two other dosage regimens, lopinavir-400mg/ritonavir-400mg and lopinavir-800mg/ritonavir-200mg co-administered with rifampin in healthy volunteers. With both doses, AUCs were reestablished, using an increased dose of only ritonavir, or a doubled dose of lopinavir/ritonavir. However, the minimum plasma concentration with the combination of lopinavir 800mg-ritonavir 200mg was lower in some timepoints than that recommended to achieve a good virologic effect. The reported adverse events, such as headache, nausea, diarrhea, fatigue and abdominal pain/cramps, were similar in both arms. However, there was a higher rate of liver toxicity in the lopinavir-400mg/ritonavir-400mg dose arm, with grade 2/3 ALT/SGTP elevations occurring in 5 subjects compared to 2 subjects in the lopinavir-800mg/ritonavir-200mg dose arm. Virological suppression was not evaluated because this was a pharmacokinetic study in healthy volunteers. In this case, liver toxicity might be explained by higher ritonavir doses, and strategies that can reduce the ritonavir dosage to permit a lower incidence of liver toxicity and other gastrointestinal events would be of extreme practical utility.
Recently, both WHO (WHO, 2003) and CDC (MMWR, 2004) recommend lopinavir 400mg-ritonavir 400mg every 12 hours in combination with rifampin in countries with limited resources, based solely in this study in healthy volunteers (La PORTE, 2004). In spite of the significant contribution to the knowledge on interaction among those drugs, this study does not reproduce the reality in clinical practice, because the volunteers were healthy, antiretroviral and anti-tuberculosis regimens were not given in full doses and lopinavir-ritonavir were introduced first and rifampin was added only after 14 days. In clinical practice, tuberculosis treatment is the priority (BRASIL, Ministério da Saúde, 2006), and the antiretroviral regimen is started later, after a period of at least 30 days, in order to observe tolerability and adverse events that usually occurs within the first month of tuberculosis treatment (PEDRAL-SAMPAIO 1997).
The scientific community reacted with surprise to this recommendation because there was no evidence in HIV-infected patients, that antiretroviral drugs and rifampin combination is as safe as described in healthy volunteers, as well as the concern about the frequency of adverse events that may occur with this combination. Furthermore, efforts have not been made to establish evidence that can support the use of a potent antiretroviral agent within the context of rescue regimens, among HAART-experienced patients. The perspective of another therapeutic possibility that may be used concomitantly with rifampin as a rescue medication in HIV-infected patients presenting tuberculosis and who have failed to antiretroviral regimen may represent the only option. Therapeutic regimens for tuberculosis without rifampin are less efficient, extend the negative baciloscopy, are associated with the biggest mortality besides being longer (1 year) and use an injectable drug during the first 3 months (streptomycin). Because lopinavir is a drug with an increased genetic barrier to resistance (MENDOZA & SORIANO, 2004) it may represent an excellent therapeutic option for patients who do not have other antiretroviral alternative.
In Brazil, the current marketed soft gel capsule formulation of Kaletra (lopinavir/ritonavir) presents some limitations such as the need for refrigeration and a moderately elevated incidence rate of diarrhea as an adverse event, between 25 to 28%, both among antiretroviral naïve and experienced patients (MURPHY et al, 2005; FEINBERG et al, 2000). Recently, the FDA (Food and Drug Administration, EUA) approved a new Kaletra (lopinavir/ritonavir) tablet formulation. The new formulation is based on a Meltrex™ (melt extrusion) technology, which requires no refrigeration (AWNI et al, 2005). Kaletra (lopinavir/ritonavir) tablets showed a lower incidence of diarrhea, in a pharmacokinetic study in healthy volunteers, when compared to other results found in studies that used the soft gel capsules (17.4%) (KLEIN et al, 2005). This scenario seems favourable for countries like Africa, where a refrigerator is a limitant condition for patients and treatment sites. A strategy of using tablets, without additional ritonavir seems promising.
Taking into account: (1) the complexity of the coinfection tuberculosis-HIV and the limited treatment options for both infections, as well as an urgent need to evaluate new options of antiretroviral regimens; (2) The results of La Porte et al (2004), that developed a pharmacokinetic study in which a pharmacokinetic drug interaction of two different doses of lopinavir/ritonavir co-administered with rifampin (600 mg/day) were evaluated; and (3) the pharmacokinetic study presented by Awni et al (2005), that showed pharmaceutic equivalence between Kaletra(lopinavir/ritonavir) soft gel capsules and tablets; we propose a clinical study in TB-HIV coinfected subjects using the association of lopinavir-ritonavir tablets and rifampin to evaluate its pharmacokinetics and safety.
This study may benefit patients co-infected with TB/HIV, particularly those with advanced immunodeficiency and who have shown failure to antiretroviral regimens including efavirenz or who may have any contraindication to their use (hypersensitivity or intolerance).
Thirty patients older than 18 years, both male and female, which present active tuberculosis and failure or contraindication for any motive to an efavirenz will be selected to participate in the study.
Antiretroviral treatment will consist of two NRTIs in combination or associated with a nucleotide analogue (tenofovir) and a combination of lopinavir-800 mg and ritonavir-200 mg (4 tablets of Kaletra) every 12 hours, daily and orally. A genotyping during screening will be conducted in order to optimize the combination therapy.
Antituberculosis treatment will consist on rifampin (600 mg/daily) isoniazide and (400 mg/daily), both in fasting condition and for 6 months; and pirazinamide (2.000 mg) for the first two months, according to the Ministry of Health recommendations. Doses will be adjusted for subjects who weight less than 45 kg. For patients who will be re-treated for tuberculosis, etambutol will be added in a dose of 1.200 mg/daily during the 6-month treatment. Those patients who need the use of any alternative regimen (without rifampin) will be excluded from study. In case of occurrence of gastrointestinal intolerance to rifampin, this one may be used after breakfast, but these data should be recorded in the patient chart in order to correlate it with pharmacokinetics data.
Lopinavir-Ritonavir should be started after 1 month after the beginning of antituberculosis treatment, at the visit of 30 days. The Lopinavir-Ritonavir dosage will be titrated during the first week of treatment, as follows:
After 6 months of tuberculosis treatment, if the patient fulfills the clinical and bacteriological criteria for cure, the antituberculosis drugs will be withdrawn and lopinavir-ritonavir (Kaletra®) will be maintained. However, the dose of Kaletra® (lopinavir/ritonavir) will be reduced to lopinavir 400mg / ritonavir 100mg (2 tablets) every 12 hours.
BERTZ A; HSU W; LAM L; ET AL. Pharmacokinetics interactions between Kaletra and other non HIV drugs. 5th International Congress on drug therapy in HIV infection. Glasgow UK October 22-26 2000. Poster 438.
BRASIL, MINISTÉRIO DA SAÚDE, 2006. Recomendações para o tratamento de adultos e adolescentes infectados pelo virus HIV.
EINBERG J, BRUN S, MARSS T, KING M, BENSON C, DEEKS S, KESSLER H, MURPHY R, GULICK R, WHEELER D, HICKS C, ERON J, SAX P, STRYKER R, RIDDLER S, THOMPSON M, REAL K, HSU A, BERTZ R, KEMPF D, JAPOUR A, SUN E. Durable Suppression of HIV+ RNA After Two Years of Kaletra (ABT-378/ritonavir) Therapy in Single Protease Inhibitor Experienced Patients. 5th International Congress on Drug Therapy in HIV Infection, Glasgow, UK (October 22-26, 2000)
LA PORTE CJL; COLBERS EPH; BERTS ET AL. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob. Agents Chemother 48:1553-1560 2004
MMWR Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or Nonnucleoside reverse transcriptase inhibitors, version 1.20.2004
MENDOZA, C. & SORIANO, V. Resistance to HIV protease inhibitors: mechanisms and clinical consequences. Curr. Drug Metab., 5(4):321-8, 2004.
MURPHY R, DA SILVA B, McMILLAN F, HICKS C, ERON J, WOLFE P, GULICK R, GLESBY M, THOMPSON M, BENSON C, WHITE AC, ALBRETCH M, KESSLER H, NIEMI K, KING K, CALHOUN D, KING M, HANNA G, BRUN S. Seven Year Follow-up of a Lopinavir/ritonavir (LPV/r)-Based Regimen in Antiretroviral (ARV)-Naïve Subjects. 10th EACS, Dublin 2005. Poster PE7.9/3.
PEDRAL-SAMPAIO DB, NETTO EM, ALCÂNTARA AP, SOUZA J, MOURA L, BRITES C ET AL. Use of Standard Therapy for Tuberculosis is Associated with Increased Adverse Reactions in Patients with HIV. BJID, 1(3): 123-130, 1997;
WHO (WORLD HEALTH ORGANIZATION). Scaling up antiretroviral therapy in resource-limited settings. Guidelines for a public health approach, 2003.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 4|
|Study Design ICMJE||Intervention Model: Single Group Assignment
Masking: None (Open Label)
|Intervention ICMJE||Drug: Lopinavir
ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
Other Name: Kaletra
Patients with HIV/TB co-infection will receive treatment for both infection, and PK of lopinavir 800mg + ritonavir 200mg (PO BID) during 5 months will be performed
Intervention: Drug: Lopinavir
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Completion Date||December 2012|
|Primary Completion Date||December 2012 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||18 Years and older (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Brazil|
|Removed Location Countries|
|NCT Number ICMJE||NCT00771498|
|Other Study ID Numbers ICMJE||A06-295|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Valeria Cavalcanti Rolla, Oswaldo Cruz Foundation|
|Study Sponsor ICMJE||Oswaldo Cruz Foundation|
|PRS Account||Oswaldo Cruz Foundation|
|Verification Date||May 2015|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP